Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies ...

Indiana's NewsCenter

Eli Lilly to pay S. Carolina $45 million
United Press International
... of schizophrenia and bipolar disorder, Eli Lilly allegedly urged doctors to prescribe it for depression, dementia and attention deficit disorder, ...
apnewsbreak: SC AG reaches $45M deal with LillyThe Associated Press

Drug maker to pay state $45 millionGreenville News

all 149 news articles »